From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-reports-top-line-results-phase-2-clinical-study-nyx-2925 NYX-2925 did not achieve statistically significant separation from placebo on primary endpoint Meaningful improvements on pain and other endpoints observed in subjects receiving 50 mg dose and in subjects not taking a concomitant analgesic medication NYX-2925 was well-tolerated with no significant adverse
From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2383056 Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS NEW YORK and IRVINE, Calif., Jan. 11, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in
From Startup BabyScripts Link to Full Article: Babyscripts, Inc., a Washington D.C.-based virtual care platform for managing obstetrics, announced today that Philips has taken a minority position in the company by leading a $6 million round of financing. The round also included participation from investors StartUp Health and NueCura Partners.
From Startup ARQULE Link to Full Article: 21% objective response rate with six confirmed partial responses from 29 evaluable patients 83% disease control rate Safety profile and tolerability of continuous dosing schedule confirmed BURLINGTON, Mass.–(BUSINESS WIRE)–Jan. 9, 2019– ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), today announced results
From Startup Genevant Link to Full Article: https://genevant.com/genevant-appoints-dr-margrit-schwarz-as-chief-scientific-officer-and-head-of-rd-and-pete-zorn-as-chief-operating-officer/ Additions bolster Genevant’s leadership position in the RNA therapeutics space with its multiple modality, “pan-RNA” approach BOSTON, MASSACHUSETTS; BURNABY, CANADA; and BASEL, SWITZERLAND – January 7, 2019 – Genevant Sciences, a leading biopharmaceutical company focused on the discovery and development of a
From Startup Heron Therapeutics Link to Full Article: https://herontherapeutics.gcs-web.com/news-releases/news-release-details/heron-therapeutics-highlights-progress-pain-management-and-cinv SAN DIEGO, Jan. 7, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its
From Startup Avrobio Link to Full Article: Industry leader brings global expertise, including as Shire’s former Global Head of Research and Development, to help further accelerate momentum and growth CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, today announced
From Startup Clinithink Link to Full Article: https://clinithink.com/clinithink-secures-growth-equity/ Leading healthcare technology investors partner with Clinithink to unlock the potential of unstructured data to inform treatment decisions, identify candidates for clinical trials, and ensure appropriate reimbursement Clinithink, which offers healthcare and life sciences organizations powerful clinical data insights through its